Atea Pharmaceuticals, Inc.

AVIR

US04683R1068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.69 ^USD	-0.27%		-0.27%	+20.98%

Mar. 27	Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	CI
Feb. 28	Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to Russell Microcap Value Index

June 24, 2022 at 12:00 am EDT

Latest news about Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	Mar. 27	CI
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Transcript : Atea Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Transcript : Atea Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	Jan. 10
Atea Pharmaceuticals Reports 'Positive' Results on Hepatitis C Virus, COVID Trials; Shares Jump After Hours	Jan. 08	MT
Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19	Jan. 08	CI
Atea Pharmaceuticals Says Bemnifosbuvir, Ruzasvir Combination Results Show Promise to Treat Hepatitis C Virus	Nov. 13	MT
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Transcript : Atea Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023	Nov. 02	CI
Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10:10 AM	23-09-13
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ
JPMorgan Downgrades Atea Pharmaceuticals to Underweight From Neutral	23-08-10	MT
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Transcript : Atea Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Value-Defensive Index	23-06-23	CI
Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index	23-06-23	CI
Atea Pharmaceuticals Doses First Patient in Phase 2 Study of Combination Therapy for Hepatitis C Virus Infection	23-06-15	MT
Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination	23-06-15	CI
Atea Pharmaceuticals Rejects Acquisition Proposal From Tang Capital Partners Affiliate Concentra Biosciences	23-05-30	MT
Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc..	23-05-29	CI
Atea Pharmaceuticals Receives Cash Takeover Proposal From Tang Capital Affiliate Concentra Biosciences; Shares Jump	23-05-22	MT
Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in Atea Pharmaceuticals, Inc. for approximately $480 million.	23-05-21	CI
Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI

Chart Atea Pharmaceuticals, Inc.

Duration

Period

More charts

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.69 USD

Average target price

4.667 USD

Spread / Average Target

+26.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ATEA PHARMACEUTICALS, INC.	+20.98%	311M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs